Clinical trials: Multiple Sclerosis Relapse
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Patient Experiences of Multiple Sclerosis (PExMS)
Besides coping with the diagnosis, people with multiple sclerosis have to make complex decisions such as deciding about immunotherapies.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Patient Engagement, Self Efficacy
- Trial name
- PExMS (NCT04236544)
- Testing
- PExMS and DECIMS-Wiki, DECIMS-Wiki
- Volunteers
- 55 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Sclerosis
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
The goal of this study was to evaluate the safety, tolerability and effectiveness of oral cladribine when taken in combination with Interferon-beta (IFN-beta) therapy for the treatment of multiple sclerosis (MS).
- Trial name
- ONWARD (NCT00436826)
- Testing
- Cladribine, Interferon-beta (IFN-beta)
- Where
- 39 sites in United States, Italy and 2 more
- Volunteers
- 172 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing-remitting Multiple Sclerosis
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
The objective of the clinical study of the medicinal product for medical use: to compare efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT02753088
- Testing
- BCD-063, Copaxone-Teva
- Volunteers
- 158 people
- Sponsor
- Biocad
Multiple Sclerosis
JC-Virus (JCV) Antibody Program
The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment.
- Trial name
- STRATIFY-1 (NCT01070823)
- Testing
- Tysabri® (natalizumab)
- Where
- 11 sites in United States
- Volunteers
- 1,096 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.
- Trial name
- NCT04997148
- Where
- 8 sites in United Kingdom
- Volunteers
- 116 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis
The aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis following optic neuritis (neuritis nervi optici) by means of a light stimulation.
- Trial name
- ONSTIM (NCT06389968)
- Testing
- Light stimulation
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Multiple Sclerosis, Relapsing-Remitting
Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis
Our project proposal is based on an individualized rehabilitation approach in patients with early stage relapsing remission (RR) MS.
- Trial name
- RELIABLE (NCT06303024)
- Testing
- personalized combined physical and cognitive intervention
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Multiple Sclerosis Relapse
Role of Virtual Reality in MS Rehabilitation
Objective: To investigate the role of virtual reality (VR) paired with robotic-assisted gait training (RAGT) compared with RAGT alone in patients with Multiple Sclerosis (MS).
- Trial name
- NCT02834533
- Testing
- Lokomat
- Volunteers
- 40 people
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost.
- Trial name
- DESIRE MS (NCT07189325)
- Testing
- Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Multiple Sclerosis
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
This study evaluates the effect of adding fish oil to Fingolimod on some serum cytokines in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- NCT02939079
- Testing
- Fingolimod, Fish Oil
- Volunteers
- 50 people
- Sponsor
- Isfahan University of Medical Sciences
Multiple Sclerosis
Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis
The primary objective was to estimate the tolerability and safety of 2 doses of teriflunomide administered once daily for 24 weeks, compared with placebo, in patients with multiple sclerosis [MS] with relapses who were on a…
- Trial name
- NCT00489489
- Testing
- Teriflunomide, Interferon-β
- Where
- 5 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Sanofi
Relapsing-Remitting Multiple Sclerosis
Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
The primary objective of the study is to evaluate whether 150 mg enteric-coated aspirin (acetylsalicylic acid [ASA]) taken twice a day (BID) with dimethyl fumarate (DMF) administration or 75 mg enteric-coated ASA taken once daily…
- Trial name
- ASSURE (NCT02090413)
- Testing
- dimethyl fumarate, acetylsalicylic acid
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 241 people
- Sponsor
- Biogen
Multiple Sclerosis
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
Multiple sclerosis (MS) is an immune-mediated disease characterized primarily by inflammatory demyelinating lesions in the central nervous system (CNS), with the white matter being predominantly affected.
- Trial name
- NCT07353216
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Relapsing-Remitting Multiple Sclerosis (RRMS)
Plegridy Satisfaction Study in Participants
The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcutaneous Interferons, as…
- Trial name
- PLATINUM (NCT02587065)
- Testing
- peginterferon beta-1a
- Where
- 30 sites in Italy
- Volunteers
- 193 people
- Sponsor
- Biogen
Multiple Sclerosis
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing…
- Trial name
- NCT03364036
- Testing
- Mavenclad®
- Where
- 54 sites in Australia, Austria and 12 more
- Volunteers
- 270 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study
The purpose of this study is to compare the effect of the Swank Diet (low saturated fat) and the Wahls Elimination Diet (modified paleo) on fatigue levels in individuals with relapsing-remitting multiple sclerosis who have…
- Trial name
- Waves (NCT02914964)
- Testing
- Swank Diet, Wahls Elimination Diet
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Terry L. Wahls
Simvastatin Multiple Sclerosis
Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis
The purpose of the clinical trial is to test how Simvastatin (80mg/day) may decrease attacks and progression of disease in patients with multiple sclerosis under disease modifying therapy (DMTs)
- Trial name
- NCT04178980
- Testing
- Simvastatin in relapsing remitting multiple sclerosis
- Volunteers
- 60 people
- Sponsor
- Assiut University
Relapsing Forms of Multiple Sclerosis
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
In this study, researchers will learn more about the study drugs diroximel fumarate (DRF) and dimethyl fumarate (DMF) in children with MS who may be experiencing relapses.
- Trial name
- VOYAGE (NCT07483632)
- Testing
- Diroximel Fumarate, Dimethyl Fumarate, Fingolimod
- Volunteers
- 185 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734). The primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo…
- Trial name
- RADIANCE (NCT01628393)
- Testing
- Ozanimod
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 258 people
- Sponsor
- Celgene
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06138132
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.